)
Endovia Health Sciences (EDVA) investor relations material
Endovia Health Sciences Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Supplement corrects voting eligibility for the November 20, 2026 annual meeting, setting total voting power at 11,339,337 after excluding Series D preferred stock.
Voting matters and shareholder proposals
October 2, 2026 record date: 11,079,337 common shares, each carrying one vote; Series A-1 preferred stock carries 260,000 votes.
Series B and Series D preferred stock are not entitled to vote at the annual meeting.
At least one-third of outstanding voting power must be present in person or by proxy to establish a quorum; abstaining shares count toward quorum.
Shareholder rights and capital structure
Outstanding preferred shares on the record date included 1,300 Series A-1, 87,999 Series B, and 5,500 Series D shares.
Share and per-share references reflect a one-for-four reverse stock split effective July 24, 2026, at 4:30 p.m. ET.
- Financing approvals and listing compliance drive the five special-meeting proposals.EDVA
Proxy filing - An ELOC-funded cannabinoid pivot faces dilution, regulatory and NYSE compliance risks.EDVA
Registration filing - Five proposals seek financing capacity and listing flexibility, with substantial dilution risk.EDVA
Proxy filing - Record date corrected to October 2 ahead of the November 20 virtual meeting.EDVA
Proxy filing - Equity-plan changes target 20% insider ownership, with potentially significant ongoing dilution.EDVA
Proxy filing - Stockholders will vote on director elections, auditor ratification, and major equity plan changes.EDVA
Proxy filing - Shareholders will vote on director elections, auditor ratification, and major equity plan changes.EDVA
Proxy filing - Strategic pivot to cannabinoid health sciences amid financial distress and high dilution risk.EDVA
Registration filing - Losses narrowed 64% as the company pivots to cannabinoid health sciences and rebrands.EDVA
Q2 2026
)
)
)
)
)
)
)
)